Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Abstract:
Traditionally, a disease has been defined by its clinical presentation and observable characteristics, not by the underlying molecular mechanisms, pathways and systems biology-related processes specific to a particular patient (ignoring persons-at-risk). A new systems approach to subclinical and/or diseased states and wellness resulted in a new trend in the healthcare services, namely, personalized and precision medicine (PPM). Despite breakthroughs in research that have led to an increased understanding of PPM-based human disease, the translation of discoveries into therapies for patients has not kept pace with medical need. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes and more cost effective use of the latest health care resources including diagnostic (companion ones), preventive and therapeutic (targeted molecular and cellular) etc. Translational researchers, bio-designers and manufacturers are beginning to realize the promise of PPM, translating to direct benefit to clinical practice. For instance, companion diagnostics tools, theranosticums, molecular imaging and targeted therapies represent important stakes for the Biopharma in terms of market access, of return on investment and of image among the prescribers. So developing the next-generation medicines and diagnostic tools requires changes to traditional clinical trial designs that result in new types of data. Making the best use of those innovations and being ready to demonstrate results for regulatory bodies requires specialized knowledge that many clinical development teams do not have. Healthcare is undergoing a transformation, and it is imperative to leverage new technologies to support the advent of PPM. And it is urgently needed to to discover, to develop and to create new (targeted and/or smart/intelligent) drugs. And with the support of nanotechnology, new targeted therapeutic agents and biomaterials, or aid the development of assays for disease biomarkers and identification of potential biomarker-target-ligand (drug) tandems to be used for the targeting, PPM is making phenomenal steps in the future to come. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM and design-driven translational medicine to elicit the content of the new trend. The latter would provide a unique platform for dialogue and collaboration among thought leaders and stakeholders in government, academia, industry, foundations, with an interest in improving the system of healthcare delivery on one hand and drug discovery, development, and translation, on the other one, whilst educating the policy community about issues where biomedical science and policy intersect. So, the Grand Change and Challenge to secure our Health and Wellness are rooted not in Medicine, and not even in Science! Just imagine WHERE?! In the upgraded Hi-Tech Culture!
Keywords: Personalized & Precision Medicine, Biomarkers, Targets, Nanoparticles, Nanocarriers, Nanotheranostics, Nanobiomedicine, Nanotechnologies
